Focus Partners Advisor Solutions LLC Sells 963 Shares of Stryker Corporation $SYK

Key Points

• Focus Partners Advisor Solutions LLC has reduced its holdings in Stryker Corporation by 1.4%, selling 963 shares and now owning 69,434 shares valued at approximately $25.8 million.
• Stryker's latest quarterly earnings report showed an earnings per share (EPS) of $3.13, surpassing the estimate of $3.07, with a revenue of $6.02 billion, which is an 11.1% increase from the previous year.
• Stryker has announced a quarterly dividend of $0.84 per share, with an annualized dividend yield of 0.9%, to be paid on October 31st to stockholders recorded by September 30th.

Focus Partners Advisor Solutions LLC decreased its position in Stryker Corporation (NYSE:SYK - Free Report) by 1.4% during the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 69,434 shares of the medical technology company's stock after selling 963 shares during the quarter. Focus Partners Advisor Solutions LLC's holdings in Stryker were worth $25,847,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the company. Flputnam Investment Management Co. lifted its holdings in Stryker by 13.0% in the first quarter. Flputnam Investment Management Co. now owns 104,147 shares of the medical technology company's stock valued at $38,769,000 after acquiring an additional 12,010 shares during the period. MAI Capital Management raised its stake in shares of Stryker by 0.9% in the first quarter. MAI Capital Management now owns 108,032 shares of the medical technology company's stock worth $40,215,000 after buying an additional 957 shares during the period. Quarry LP raised its stake in shares of Stryker by 83.3% in the first quarter. Quarry LP now owns 187 shares of the medical technology company's stock worth $70,000 after buying an additional 85 shares during the period. Saudi Central Bank bought a new position in shares of Stryker in the first quarter worth about $50,000. Finally, Brasada Capital Management LP raised its stake in shares of Stryker by 1.3% in the first quarter. Brasada Capital Management LP now owns 17,419 shares of the medical technology company's stock worth $6,484,000 after buying an additional 229 shares during the period. Institutional investors own 77.09% of the company's stock.

Insider Activity at Stryker

In other news, insider Viju Menon sold 500 shares of the firm's stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $390.61, for a total value of $195,305.00. Following the completion of the sale, the insider directly owned 12,511 shares of the company's stock, valued at $4,886,921.71. This trade represents a 3.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Ronda E. Stryker sold 200,000 shares of the firm's stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total value of $75,290,000.00. Following the completion of the sale, the director directly owned 3,222,108 shares of the company's stock, valued at $1,212,962,556.60. The trade was a 5.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.20% of the stock is owned by company insiders.

Stryker Stock Performance

NYSE SYK opened at $391.48 on Monday. The stock has a market capitalization of $149.67 billion, a PE ratio of 51.85, a P/E/G ratio of 2.85 and a beta of 0.93. The business has a 50 day simple moving average of $389.26 and a two-hundred day simple moving average of $379.33. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. Stryker Corporation has a 1-year low of $329.16 and a 1-year high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, beating the consensus estimate of $3.07 by $0.06. The business had revenue of $6.02 billion during the quarter, compared to analysts' expectations of $5.92 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The firm's revenue for the quarter was up 11.1% compared to the same quarter last year. During the same quarter last year, the business posted $2.81 EPS. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, research analysts predict that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 0.9%. The ex-dividend date of this dividend is Tuesday, September 30th. Stryker's dividend payout ratio (DPR) is presently 44.50%.

Analyst Ratings Changes

SYK has been the topic of several recent research reports. Citigroup reaffirmed a "buy" rating and issued a $455.00 price objective (up previously from $443.00) on shares of Stryker in a research note on Thursday, May 22nd. Evercore ISI raised their price objective on Stryker from $390.00 to $415.00 and gave the stock an "outperform" rating in a research note on Tuesday, July 8th. BTIG Research reaffirmed a "buy" rating on shares of Stryker in a research note on Monday, July 14th. Sanford C. Bernstein set a $450.00 price objective on Stryker in a research note on Monday, May 5th. Finally, JMP Securities reaffirmed a "market perform" rating on shares of Stryker in a research note on Monday, May 5th. Fifteen analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, Stryker presently has a consensus rating of "Moderate Buy" and a consensus target price of $430.10.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.